Open AccessSerum butyrylcholinesterase and zinc in breast cancer
Author(s) -
Rupesh Kumar,
Sairoz Razab,
Krishnananda Prabhu,
Sujoy Ray,
Bhanu Prakash
Publication year - 2017
Publication title -
journal of cancer research and therapeutics/journal of cancer research and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.475
H-Index - 39
eISSN - 0973-1482
pISSN - 1998-4138
DOI - 10.4103/0973-1482.165869
Subject(s) - butyrylcholinesterase , breast cancer , cancer , medicine , carcinogenesis , serology , oncology , gastroenterology , immunology , biology , antibody , enzyme , biochemistry , aché , acetylcholinesterase
Even though, a large number of serological, molecular markers have been proposed for breast cancer screening, most of them lack specificity, sensitivity, prognostic value, and cost effectiveness. Butyrylcholinesterase (BChE) and its genes are aberrantly expressed in a variety of human cancers. It has-been linked to tumorigenesis, cell proliferation, and cell differentiation. Zinc (Zn) is a cofactor for superoxide dismutase, an enzyme that protects cellular components against free radical-induced damage and carcinogenesis. Therefore, the aim of present study was to estimate and compare serum BChE and serum Zn levels in healthy controls and biopsy proven breast cancer patients before definitive therapy.